Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Clinical Studies

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

British Journal of Cancer volume 126, pages 1394–1400 (2022)Cite this article

Subjects

A Correction to this article was published on 11 February 2022

This article has been updated

Abstract

Background

Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist. This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for mPA after FFX failure.

Methods

In this retrospective real-world multicenter study, from 2011 to 2019, patients with mPA receiving Gem-Nab (Gem 1000 mg/m² + Nab 125 mg/m², 3 out of 4 weeks) or Gem alone were included after progression on FFX.

Results

A total of 427 patients were included. Patients receiving Gem-Nab had more metastatic sites, peritoneal disease and less PS 2 (24% vs. 35%). After median follow-up of 22 months, Gem-Nab was associated with better disease control rate (DCR) (56% vs. 32%; P < 0.001), progression-free survival (PFS) (3.5 vs. 2.3 months; 95% CI: 0.43–0.65) and overall survival (OS) (7.1 vs. 4.7 months; 95% CI: 0.53–0.86). After multivariate analysis, Gem-Nab and PS 0/1 were associated with better OS and PFS. Grade 3/4 toxicity was more frequent with Gem-Nab (44% vs. 29%).

Conclusion

In this study, Gem-Nab was associated with better DCR, PFS and OS compared with Gem alone in patients with mPA after FFX failure, at the cost of higher toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Progression-free and overall survival.
Fig. 2: Subgroup analysis of survival.

Similar content being viewed by others

Change history

References

  1. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5:2649–56. https://doi.org/10.1002/cam4.767

    Article  PubMed  PubMed Central  Google Scholar 

  2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud, Yves B, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl J Med. 2011;2011:1817–25.

    Article  Google Scholar 

  3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (MPACT Trial). N. Engl J Med. 2013;369:1691–703. https://doi.org/10.1056/NEJMoa1304369

    Article  CAS  Google Scholar 

  4. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. JCO. 2014;32:2423–9. https://doi.org/10.1200/JCO.2013.53.6995

    Article  CAS  Google Scholar 

  5. Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87. https://doi.org/10.1016/j.ejca.2018.12.007

    Article  CAS  PubMed  Google Scholar 

  6. Gill S, Ko Y-J, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. JCO. 2016;34:3914–20. https://doi.org/10.1200/JCO.2016.68.5776

    Article  CAS  Google Scholar 

  7. Mercadé TM, Chen L-T, Li C-P, Siveke JT, Cunningham D, Bodoky G, et al. Liposomal Irinotecan + 5-FU/LV in metastatic pancreatic cancer. Pancreas. 2020;49:14 https://doi.org/10.1097/MPA.0000000000001455

    Article  Google Scholar 

  8. Sarabi M, Mais L, Oussaid N, Desseigne F. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917–24. https://doi.org/10.3892/ol.2017.6061

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, et al. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine. 2017;96:e6544 https://doi.org/10.1097/MD.0000000000006544

    Article  PubMed  PubMed Central  Google Scholar 

  10. Girardi DM, Faria LDBB, Teixeira MC, Costa FP, Hoff PMG, Fernandes GS. Second-line treatment for advanced pancreatic adenocarcinoma: is there a role for gemcitabine. J Gastrointest Canc. 2019;50:860–6. https://doi.org/10.1007/s12029-018-0166-4

    Article  CAS  Google Scholar 

  11. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113:989–95. https://doi.org/10.1038/bjc.2015.328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JCO. 1997;15:2403–13. https://doi.org/10.1200/JCO.1997.15.6.2403

    Article  CAS  Google Scholar 

  13. Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, et al. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol. 2019;36:83 https://doi.org/10.1007/s12032-019-1306-9

    Article  CAS  PubMed  Google Scholar 

  14. Hasegawa R, Okuwaki K, Kida M, Yamauchi H, Kawaguchi Y, Matsumoto T, et al. A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer. Int J Clin Oncol. 2019;24:1574–81. https://doi.org/10.1007/s10147-019-01511-0

    Article  CAS  PubMed  Google Scholar 

  15. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, et al. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharm. 2014;73:839–45. https://doi.org/10.1007/s00280-014-2414-z

    Article  CAS  Google Scholar 

  16. Yoo C, Hwang JY, Kim J-E, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658–63. https://doi.org/10.1038/sj.bjc.6605374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart A-C, Lecomte T, et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer. 2014;14:441 https://doi.org/10.1186/1471-2407-14-441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–81. https://doi.org/10.1016/j.ejca.2011.04.011

    Article  CAS  PubMed  Google Scholar 

  19. Scripture C, Figg W, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. CN. 2006;4:165–72. https://doi.org/10.2174/157015906776359568

    Article  CAS  Google Scholar 

  20. Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, et al. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer. 2020;20:259 https://doi.org/10.1186/s12885-020-06758-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tsang ES, Spratlin J, Cheung WY, Kim CA, Kong S, Xu Y, et al. Real-world outcomes among patients treated with gemcitabine-based therapy post-FOLFIRINOX failure in advanced pancreatic cancer. Am J Clin Oncol. 2019;42:903–8. https://doi.org/10.1097/COC.0000000000000625

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all investigators of the AGEO (Association des Gastro-Entérologues Oncologues) group for their support and participation to this project. Presented in part as a poster discussion at the World Congress on Gastrointestinal Cancer 2020 (Barcelona, Spain).

Funding

None.

Author information

Authors and Affiliations

  1. Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France

    Sonia Zaibet & Julien Taieb

  2. Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France

    Vincent Hautefeuille & Julie Wasselin

  3. Department of Medical Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France

    Edouard Auclin

  4. INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers, Université de Paris, Paris, France

    Edouard Auclin

  5. Department of Gastroenterology, CHU Rennes, INSERM U1242, Rennes, France

    Astrid Lièvre

  6. Department of Hepato-Gastroenterology, CHU Poitiers, Poitiers, France

    David Tougeron

  7. Department of Medical Oncology, Centre Léon Bérard, Lyon, France

    Mathieu Sarabi & Clémence Morin

  8. Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

    Marine Gilabert

  9. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

    Julien Edeline

  10. Department of Hepato-Gastroenterology, Hôpital Privé Jean Mermoz, Lyon, France

    Pascal Artru

  11. Department of Medical Oncology, Institut Bergonié, Bordeaux, France

    Dominique Bechade & Simon Pernot

  12. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France

    Agnes Ducoulombier

Authors
  1. Sonia Zaibet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent Hautefeuille
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edouard Auclin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Astrid Lièvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Tougeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mathieu Sarabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marine Gilabert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Julie Wasselin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Julien Edeline
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pascal Artru
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dominique Bechade
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Clémence Morin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Agnes Ducoulombier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Julien Taieb
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Simon Pernot
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception/design of the work: SZ, JT and SP. Acquisition of the data: SZ, VH, AL, DT, MS, MG, JW, JE, PA, DB, CM, AD, JT and SP. Analysis of the data: SZ, VH, EA, JT and SP. Interpretation of the data: SZ, VH, EA, JT and SP. Drafting the work: SZ, VH, EA, JT and SP. Revising it critically: all. Final approval of the version to be published: all.

Corresponding author

Correspondence to Simon Pernot.

Ethics declarations

Ethics approval and consent to participate

All patients alive at the time of data collection were informed before being enrolled in this study by written information. This study was performed in accordance with the Declaration of Helsinki. The collection and the treatment of the data were conducted according to the MR 004 authorisation, registered at the Commission National Informatique et Liberté (CNIL).

Consent to publish

Not applicable.

Competing interests

SZ, MS, MG, JW, DB, CM and AD declare no competing interests. V. Hautefeuille: lectures: AAA, Novartis, Ipsen, Amgen, Merck, Sanofi. Advisory for AAA, Novartis, Ipsen, Amgen, Merci, Sanofi. Travel support: AAA, Novartis, Ipsen, Amgen, Pfizer, Servier. E Auclin: travel expenses: Mundipharma. Lectures and educational activities: Sanofi Genzymes. A. Lièvre: honoraria for lectures from AAA, Amgen, Bayer, BMS, HalioDx, Incyte, Ipsen, Merck, Novartis, Pierre Fabre, Roche, Sandoz, Sanofi and Servier and for consulting/advisory relationship from AAA, Amgen, Bayer, Incyte, Ipsen, Merck, Novartis Pierre Fabre, Sandoz and Servier. Travel (or subscription to congress) support from AAA, Bayer, Ipsen, Merck, Mylan, Novartis, Pfizer, Roche and Servier. D. Tougeron: honoraria from AstraZeneca, Bayer, BMS, IPSEN, MERCK, MSD, Roche, Sanofi, Servier, Amgen, Pierre Fabre. J Edeline: honoraria from Roche, Bayer, Ipsen, MSD, BMS, Eisai, Boston Scientific, AstraZeneca. P. Artru: honoraria as a speaker and/or in an advisory role from Roche Genentech, Servier, Pierre Fabre, Amgen, Merck and Bayer. J Taieb: honoraria as a speaker and/or in an advisory role from Merck KGaA, Sanofi, Roche Genentech, MSD, Lilly, AstraZeneca, Servier, Novartis, Pierre Fabre, HallioDx and Amgen. S Pernot: SP declares honoraria for the speaker or advisory roles for Amgen, Roche, Merck KGaA, Servier, Sanofi, Pierre Fabre, AstraZeneca.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In this article the author name Sonia Zaibet was incorrectly written as Simon Zaibet. The original article has been corrected.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaibet, S., Hautefeuille, V., Auclin, E. et al. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Br J Cancer 126, 1394–1400 (2022). https://doi.org/10.1038/s41416-022-01713-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-01713-w

This article is cited by

Search

Advanced search

Quick links